ARCHIVED - Public Health Agency of Canada - Supplementary Tables

Name of Horizontal Initiative:  Federal Initiative to Address HIV/AIDS in Canada (FI)

Name of Lead Department(s): Public Health Agency of Canada (the Agency)

Lead Department Program Activity: Disease and Injury Prevention and Mitigation

Start Date of the Horizontal Initiative: January 13, 2005

End Date of the Horizontal Initiative: Ongoing

Total Federal Funding Allocation (Start to End Date): Ongoing

Description of the Horizontal Initiative (Including Funding Agreement): The FI strengthens domestic action on HIV and AIDS, builds a coordinated Government of Canada approach, and supports global health responses to HIV and AIDS. It focuses on prevention and access to diagnosis, care, treatment and support for those populations most affected by HIV and AIDS in Canada — people living with HIV and AIDS, gay men, Aboriginal people, people who use injection drugs, federal inmates, youth, women, and people from countries where HIV is endemic. The FI also supports and strengthens multi-sector partnerships to address the determinants of health. It supports collaborative efforts to address factors which can increase the transmission and acquisition of HIV including sexually transmitted infections (STI) and also addresses co-infection issues with other infectious diseases (e.g., Hepatitis C and tuberculosis) from the perspective of disease progression and morbidity in people living with HIV and AIDS. People living with and vulnerable to HIV and AIDS are active partners in shaping policies and practices affecting their lives.

*Shared Outcome(s):

First level outcomes

• Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease;
• Increased individual and organizational capacity;
• Increased Canadian engagement and leadership in the global context; and
• Enhanced engagement and collaboration on approaches to address HIV and AIDS.

Second level outcomes

• Reduced stigma, discrimination, and other barriers;
• Improved access to more effective prevention, care, treatment and support;
• Internationally informed federal response; and
• Increased coherence of the federal response.

Ultimate outcomes

• Prevent the acquisition and transmission of new infections;
•  
• Improved quality of life for those at risk and living with HIV and AIDS;
• Contribute to the global effort to reduce the spread of HIV and AIDS and mitigate its impact; and
• Contribute to the strategic outcomes of partner departments.

*Shared Outcomes have been refined in response to an April 2009  Federal Initiative (FI) to Address HIV/AIDS in Canada Implementation Evaluation Report, which recommended strengthening of the FI’s performance measurement framework.

Governance Structure(s): The Responsibility Centre Committee (RCC) is the governance body for the FI. It is comprised of directors from the nine Responsibility Centres which receive funding through the FI. Led by the Agency, the RCC promotes policy and program coherence among the participating departments and agencies, and ensures that evaluation and reporting requirements are met.

The  Agency is the federal lead for issues related to HIV and AIDS in Canada responsible for overall coordination, communications, social marketing, reporting, evaluation, national and regional programs, policy development, surveillance and laboratory science.

 Health Canada (HC) supports community-based HIV and AIDS education, capacity-building, and prevention for First Nations on-reserve and Inuit communities south of the 60th degree parallel and provides leadership on international health policy and program issues.

As the Government of Canada’s agency for health research, the  Canadian Institutes of Health Research (CIHR) sets priorities for and administers the extramural research program.

 Correctional Service Canada (CSC), an agency of the  Public Safety Portfolio, provides health services (including services related to the prevention, diagnosis, care and treatment of HIV and AIDS) to offenders sentenced to two years or more.

Planning Highlights: Provide inter-sectoral leadership on common approaches to monitoring systems and to program interventions in order to prevent and control HIV and AIDS and related infectious diseases in Canada.

Federal Partner: The Agency
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Science and Technology for Public Health	HIV/AIDS Reference Testing and Quality Assurance	Ongoing	2.9	ER 1.1  ER 1.2
Surveillance and Population Health Assessment	Surveillance of Infectious Disease	Ongoing	4.5	ER 2.1
Disease and Injury Prevention and Mitigation	Infectious Disease Prevention and Control and Community Associated Infections	Ongoing	34.9	ER 3.1  ER 3.2  ER 3.3
Total Agency			42.3

Expected Results:

ER 1.1: Public health decisions and interventions by public health officials are supported by timely, reliable and accredited reference service testing that accurately captures all the circulating HIV strains in Canada and directs attention to new outbreaks and increases in HIV transmission.

1. Identify best treatments for reduced mother to child transmission.
2. Develop standards and methods for testing.
3. Improve understanding of HIV variation.
4. Provide drug resistance information that will guide treatment selection for treatment-naïve patients.
5. Monitor quality of HIV testing in Canada.

ER 1.2: Use of laboratory-generated knowledge is increased.

1. Develop linkages with epidemiologists and other social scientists to examine magnitude of HIV test results and social determinants that have an influence in HIV infected persons.
2. Identify, confirm, and provide recommendations to address performance of HIV diagnostic test kits in Canada.
3. Collaborate with the Canadian Association of HIV Clinical Laboratory Specialists on standards development for increased quality of HIV diagnostic, prognostic, and drug resistance testing.
4. Collaborate with the Standards Council of Canada and the Clinical Laboratory Standards Institute on the creation and implementation of quality standard guidelines/practices in medical laboratories in Canada and worldwide.
5. Disseminate technical information to partners on HIV testing to enhance quality, reliability, and comparability.
6. Collaborate with CIHR and the British Columbia Centre for Disease Control on funded projects including HIV transmission patterns in at-risk communities in Vancouver in order to determine whether new infections are over-represented.

ER 2.1: Trends are monitored and assessed in reported HIV infections, and patterns of prevalence and risk and health behaviours related to HIV and associated infections among populations most affected by HIV and AIDS in Canada are assessed. This will be achieved by designing and implementing targeted survey data collection, analysis, and interpretation, as well as knowledge transfer and exchange. These efforts will particularly be focussed in areas and in populations that have noted recent increases in HIV infection rates, such as Aboriginal persons in Saskatchewan who inject drugs.

ER 3.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease, as indicated by:

1. The number and type of evidence-based information products developed and disseminated, including the national report on HIV/AIDS Surveillance; the National Report on HIV Drug Resistance Surveillance; comparative international studies of HIV incidence and prevalence; three population-specific reports; an HIV prevention and related co-infection framework; HIV counselling and testing guidelines and a chapter on disclosure; the Canadian Guidelines on Sexually Transmitted Infections; Canadian Sexual Health Education Guidelines information products; interdepartmental pilot projects to address HIV and the determinants of health; augmented HIV case reporting; targeted epidemiological studies among most at risk populations; improved knowledge and characterization of HIV strains in Canada; and implementation of recommendations from the PHAC study of HIV and AIDS funding programs’ structure;
2. Ongoing support and guidance provided to partners, including the number and type of knowledge and awareness activities and products, and processes to develop funding proposals aligned with public health priorities;
3. Project data on number of presentations and workshops and their reach;
4. Project data on increases in knowledge of HIV transmission and risk factors among target populations;
5. Identification of novel transmission mechanisms of HIV infection; and
6. The efficacy of policies aimed at addressing HIV transmission.

ER 3.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS, as indicated by:

1. Intersectoral leadership;
2. Coordinated approaches to data collection and dissemination, enhanced collaboration with key stakeholders in the response to HIV and AIDS, and STI’s, including committees, partnerships and collaborative documents;
3. Focussed advisory and coordination agendas that link to FI expected results;
4. Engagement of community organisations in the response to HIV and AIDS and the factors that impact those affected and at risk for infection;
5. The number of invitations to submit applications and the number of funded project proposals;
6. Project data on number and type of partnerships; and,
7. On-going guidance provided to NGO partners.

ER 3.3: Increased individual and organizational capacity to address HIV and AIDS, as indicated by:

1. The accessibility, quality and reliability of HIV molecular diagnostic and monitoring assays;
2. The development and implementation of effective interventions for the prevention and control of infectious diseases in community settings;
3. Sustained support to community-based organizations, including the number of projects funded and funds provided to community-based funding;
4. The number of projects in which target populations contribute to management and delivery of projects;
5. The number and type of capacity building activities for non-governmental and community-based organizations;
6. Project data on actions to improve access to health and social services;
7. Project data on number of volunteers and volunteer hours;
8. Improved methods for determining the immune health of people with HIV; and
9. Identifying key prevention strategies for vulnerable groups.

Federal Partner: Health Canada
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Internal Services	Governance and Management Support Services	Ongoing	0.9	ER 4.1  ER 4.2
First Nations and Inuit Primary Health Care	Bloodborne Diseases and Sexually Transmitted Infections — HIV/AIDS	Ongoing	4.5	ER 5.1  ER 5.2
Total HC			5.4

Expected Results:

ER 4.1: Increased Canadian engagement and leadership in the global context through exchanging best practices with global partners to inform global and domestic policies on HIV and AIDS. This will be achieved by supporting the development and dissemination of information, and through increased dialogue and engagement with stakeholders and other Government of Canada departments in three global fora to share expertise and influence policies.

ER 4.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS through supporting the development of advice documents to inform global collaboration on HIV and AIDS and policy coherence across federal government’s global activities on HIV and AIDS.

ER 5.1: Areas for improved programming regarding HIV-blood borne sexually transmitted infections (HIV-BBSTI) and tuberculosis (TB) co-infections are identified via enhanced engagement and collaboration on approaches to address underlying factors related to HIV and AIDS through partnerships with the  National Native Alcohol and Drug and Alcohol Abuse Program (NNADAP) and the First Nations and Inuit Health Branch’s TB Program.

ER 5.2: Increased individual and organizational capacity to address HIV and AIDS, as indicated by the:

1. Development of a training module to be used by NNADAP workers and community nurses in HIV-BBSTI risk factors;
2. Number of community nurses receiving training on HIV-BBSTI and related health issues; and
3. Number of NNADAP workers receiving training on HIV-BBSTI risk factors and the need for HIV testing.

Federal Partner: Canadian Institutes of Health Research
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Health and Health Services Advances	HIV and AIDS Research Initiative	Ongoing	21.0	ER 6.1  ER 6.2  ER 6.3  ER 6.4
Total CIHR			21.0

Expected Results:

ER 6.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease through the funding of high-quality research and knowledge translation grants in HIV and AIDS. This will be achieved through the ongoing development and administration of strategic research funding programs.

ER 6.2: Increased individual and organizational capacity for HIV and AIDS research through the funding of high-quality capacity-building grants and awards in HIV and AIDS. This outcome is achieved through the ongoing development and administration of strategic research capacity-building funding programs.

ER 6.3: Enable Canadian participation and leadership in HIV/AIDS research in the global context through the funding of internationally focused research projects and partnerships and contributing to relevant FI activities.

ER 6.4: Enhanced engagement and collaboration on approaches to address HIV/AIDS through on-going participation in FI committees and activities and the development of collaborative activities to address common priorities.

Federal Partner: Correctional Services Canada
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Custody	Institutional Health Services Public Health Services	Ongoing	4.2	ER 7.1  ER 7.2
Total CSC			4.2

Expected Results:

ER 7.1: Increased knowledge and awareness of the nature of HIV and AIDS and ways to address the disease, as indicated by the percentage of federal offenders who indicate improved general knowledge of HIV and AIDS after attending CSC’s Peer Education Course.

ER 7.2: Enhanced engagement and collaboration on approaches to address HIV and AIDS through the Federal/Provincial/Territorial Heads of Corrections Working Group on Health. The emphasis will be on developing and strengthening partnerships with: provincial and territorial governments involved in addressing HIV/AIDS and sexually transmitted and blood borne infections; federal departments at national and regional levels (e.g., PHAC, First Nations and Inuit Health Branch of Health Canada); and the Council of Chief Medical Officers of Health.

($ M)

Total Allocation for All Federal Partners (from Start to End Date)	Total Planned Spending for All Federal Partners for 2011-12
Ongoing	72.9

Results to be Achieved by Non-Federal Partners (if Applicable): N/A

Contact Information:
Stephanie Mehta
100 Eglantine Drive
Ottawa, ON K1A 0K9
613-954-4502
stephanie.mehta@phac-aspc.gc.ca

Name of Horizontal Initiative: Preparedness for Avian and Pandemic Influenza Initiative

Name of Lead Department(s): Public Health Agency of Canada (the Agency)

Lead Department Program Activities:

• Public Health Preparedness and Capacity
• Disease and Injury Prevention and Mitigation
• Surveillance and Population Health Assessment
• Science and Technology for Public Health
• Regulatory Enforcement and Emergency Response

Start Date of the Horizontal Initiative: June 21, 2006

End Date of the Horizontal Initiative: Ongoing

Total Federal Funding Allocation (Start to End Date): Ongoing

Description of the Horizontal Initiative (Including Funding Agreement): This initiative is directed at mitigating Canada’s risk from two major, inter-related animal and public health threats: the potential spread of avian influenza (AI) virus (i.e., H5N1) to wild birds and domestic fowl in Canada; and, the potential for a human-adapted strain to arise resulting in human-to-human transmission potentially triggering a human influenza pandemic. A coordinated and comprehensive plan to address both avian and pandemic influenza is maintained.

The bulk of the initiative is ongoing. Activities have been launched in the areas of vaccines and antivirals, surge capacity, prevention and early warning, emergency preparedness, critical science and regulation, risk communication, and inter-jurisdictional collaboration. To enhance the federal capacity to address an on-reserve pandemic, efforts have been made to increase surveillance and risk assessment capacity to fill gaps in planning and preparedness.

Shared Outcome(s):

Immediate Outcomes

• Strengthened Canadian capacity to prevent and respond to pandemics; and
• Increased internal and external awareness, knowledge and engagement with stakeholders.

Intermediate Outcomes

• Increased prevention, preparedness and control of challenges and emergencies related to AI/PI; and
• Strengthened public health capacity.

Long-Term and Strategic Outcomes

• Increased/reinforced public confidence in Canada’s public health system; and
• Minimization of serious illness, overall deaths, and societal disruption as a result of an influenza pandemic

Governance Structure(s): In January 2008, the  Agency, the  Canadian Institutes of Health Research, the  Canadian Food Inspection Agency and  Health Canada  finalized the Avian and Pandemic Influenza Preparedness Interdepartmental/Agency Governance Agreement. The primary scope of the Agreement is the management of specific horizontal issues and/or initiatives relating to avian and pandemic influenza preparedness.

The Agreement is supported by a structure that falls within the auspices of the Deputy Minister’s Committee on Avian and Pandemic Influenza Planning. Implementation of the Agreement is led by the Avian and Pandemic Influenza Assistant Deputy Ministers (API ADM) Governance Committee focusing on implementation of the initiatives. The API ADM Governance Committee provides strategic direction and oversight monitoring.

An Avian and Pandemic Influenza Operations Directors General Committee supports the API ADM Governance Committee, makes recommendations to it and oversees the coordination of deliverables.

Planning Highlights: In 2011-12 the Agency, working collaboratively with Health Canada, the Canadian Institutes for Health Research and the Canadian Food Inspection Agency, intends to expand upon previous activities in avian and pandemic influenza preparedness, through the continuation of the vaccine readiness strategies, antivirals, surge capacity, prevention and early warning, emergency preparedness, critical science and regulation, risk communication, and inter-jurisdictional collaboration. Planned activities and expected results reflect lessons learned from the H1N1 pandemic, notably the Management Response and Action Plan (MRAP) following the Senate study.

Federal Partner: The Agency
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Science and Technology for Public Health	Rapid vaccine development and testing	Ongoing	1.0	ER 1.1
	Winnipeg lab and space optimization	Ongoing	18.8	ER 2.1
Surveillance and Population Health Assessment	Surveillance	Ongoing	8.7	ER 3.1
Public Health Preparedness and Capacity	Vaccine readiness and clinical trials	Ongoing	3.6	ER 4.1
	Capacity for pandemic preparedness	Ongoing	5.2	ER 5.1
	Emergency preparedness	Ongoing	6.0	ER 6.1  ER 6.2  ER 6.3  ER 6.4  ER 6.5  ER 6.6
	Emergency human resources	Ongoing	0.4	ER 7.1
	Strengthening the public health laboratory network	Ongoing	1.2	ER 8.1  ER 8.2  ER 8.3
	Influenza research network	Ongoing	1.8	ER 9.1
	Pandemic influenza risk assessment and modelling	Ongoing	0.8	ER 10.1  ER 10.2
	Evaluation	Ongoing	0.6	ER 11.1  ER 11.2  ER 11.3
	Pandemic influenza risk communications strategy	Ongoing	1.8	ER 12.1  ER 12.2
	Skilled national public health workforce	Ongoing	5.9	ER 13.1  ER 13.2  ER 13.3  ER 13.4
Regulatory Enforcement and Emergency Response	Contribution to National Antiviral Stockpile	Ongoing	0.1	ER 14.1  ER 14.2  ER 14.3
Total Agency			55.9

Expected Results:

ER 1.1: Progress made on the development of different clinical-grade commercial H5N1 influenza vaccines.

ER 2.1: Construction of the new lab is 60% completed, therefore increased research capacity underway.

ER 3.1: Capacity to rapidly identify and report human cases of avian and pandemic influenza and public health events of international concern is improved though the revamping of the current severe respiratory illness early detection system which includes a pilot study on the Intensive Care Unit (ICU) reporting system.

ER 4.1: Capacity for vaccine-adverse event surveillance and effectiveness monitoring during a pandemic is improved through upgrades to the current Canadian Adverse Events Following Immunization Surveillance System (CAEFISS) database to ensure maximum functionality.

ER 5.1: Capacity for increased use of the regional communication systems is improved through the regional Public Health Capacity program.

ER 6.1: Response mechanisms are established to respond to an avian or pandemic influenza outbreak in accordance with the World Health Organization (WHO) and Canadian Pandemic Influenza Plan (CPIP).

ER 6.2: The National Microbiology Laboratory (NML) is capable of working with certified influenza strains as the lead influenza reference centre for Canada.

ER 6.3: Quarantine entry and exit screening options are developed and assessed for use during all phases of a pandemic.

ER 6.4: The Health Portfolio Emergency Operations Centre is maintained in a state of readiness.

ER 6.5: Incident response plans are maintained with provincial and territorial departments and non-governmental organizations through testing exercises where the testing criteria are established on lessons learned and through the after action reports and plans which are revised, updated and maintained regularly.

ER 6.6: Increased efficiency and effectiveness of regional resources placed to facilitate the flow of information between federal, provincial and territorial levels through the regional public health capacity program.

ER 7.1: An updated Human Resources Emergency Response Plan is implemented by end of fiscal year 2011-12.

ER 8.1: The current number of equipped and trained federal laboratory liaison technicians in place in provinces and territories will be maintained.

ER 8.2: Communications between provincial and territorial labs and the NML is improved thereby strengthening the national lab’s capacity through a series of meetings throughout the year.

ER 8.3: Components of the Canadian Pandemic Influenza Plan’s Annex C (Pandemic Influenza Laboratory Guidelines) are updated as a result of the H1N1 pandemic.

ER 9.1: Research resources are optimally allocated through proactive research protocols and international collaboration to respond to the needs of avian and pandemic influenza preparedness.

ER 10.1: Predictive and assessment models used for pandemic preparedness are developed and established.

ER 10.2: More potential learners in university and college settings are being trained as mathematical modelers to augment public health capacity in mathematical modeling.

ER 11.1: Evaluation improvements proposed in the Evaluation Plan for avian and pandemic influenza preparedness are implemented.

ER 11.2: Components of the performance measurement framework are in place at the responsibility-centre level.

ER 11.3: Performance data and evidence are collected using a Web-based system and are used for management and reporting.

ER 12.1: Social marketing plans and activities are reviewed and appropriate modifications have been made in light of the H1N1 experience.

ER 12.2: H1N1 lessons learned in communicating with stakeholders during a pandemic influenza are addressed.

ER 13.1: Letters of Agreement with selected placement sites for public health officers across the country are completed.

ER 13.2: Public health officers and Canadian Public Health Service regional coordinators are in place across Canada.

ER 13.3: Training modules continue to be developed, and new and existing modules are made available to public health officers in the field.

ER 13.4: Competency profiles for public health officers are developed.

ER 14.1: Lead time on an outbreak of a pandemic is improved through information sharing, international collaborations and increased surveillance systems.

ER 14.2: Pandemic vaccine availability is improved by optimizing the approval processes.

ER 14.3: The National Antiviral Stockpile is maintained and plans are established for the replacement of antiviral stocks as they reach the end of their shelf-life.

Federal Partner: Health Canada
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Health Products	Regulatory activities related to pandemic influenza vaccine	Ongoing	1.1	ER 15.1  ER 15.2  ER 15.3  ER 15.4  ER 15.5  ER 15.6
	Resources for review and approval of antiviral drug submissions for treatment of pandemic influenza	Ongoing	0.2	ER 16.1  ER 16.2  ER 16.3
	Establishment of a crisis risk management unit for monitoring and post-market assessment of therapeutic products	Ongoing	0.3	ER 17.1  ER 17.2
Health Infrastructure Support for First Nations and Inuit	Strengthen federal public health capacity through Governance and Infrastructure Support to FN/I Health System	Ongoing	0.7	ER 18.1  ER 18.2  ER 18.3  ER 18.4  ER 18.5
	FN/I emergency preparedness, planning, training and integration	Ongoing	0.3	ER 19.1
Specialized Health Services	Public health emergency preparedness and response (EPR) on conveyances	Ongoing	0.3	ER 20.1
Total HC			2.9

Expected Results:

ER 15.1: World Health Organization (WHO) Guidance on Regulatory Preparedness for Human Pandemic Influenza Vaccines is revised and updated as required.

ER 15.2: Finalize Extraordinary Use New Drugs (EUND) regulations and develop accompanying guidance document.

ER 15.3: Maintain links established with international regulatory bodies (WHO, Chinese State Food and Drug Administration, United States, Europe, Australia) by continuing to participate in regulatory and technical initiatives which increase the timeliness and availability of information in the event of a pandemic (i.e., pandemic influenza strain).

ER 15.4: Review response to the H1N1 events and produce and implement lessons learned.

ER 15.5: Continue coordinating blood system preparedness through regular teleconferences and regulatory advice/decisions to Canadian Blood Services and Headquarters. Share lessons learned and better practices with WHO Blood Regulators Network.

ER 15.6: Work with the WHO to develop recommendations for new pneumococcal conjugate vaccine through the WHO Expert Committee on Biologic Standardization.

ER 16.1: Complete review of any anti-viral submissions that may be received.

ER 16.2: Finalize Expedited Pandemic Influenza Drug Review (EPIDR) Protocol, incorporating H1N1 pandemic experiences.

ER 16.3: Ongoing on-the-job reviewer training for the accelerated review. Review procedures for antivirals submissions, before and during pandemic occurrences are established.

ER 17.1: Maintenance of the crisis risk management unit.

ER 17.2: Ongoing post-market assessment of therapeutic products.

ER 18.1: Educational initiatives regarding passenger conveyance of infection control are integrated into program activities, training and outreach to conveyance operators.

ER 18.2: Collaborate with PHAC, the Public Service Commission, and Indian and Northern Affairs Commission for planning and response.

ER 18.3: Work on surveillance needs with PHAC.

ER 18.4: Enhanced federal capacity to support First Nations communities in planning and responding to a pandemic.

ER 18.5: Increase links with national and regional Emergency Preparedness and Response program staff and with provinces and territories.

ER 19.1: Continue to support the testing and revision of community pandemic plans.

ER 20.1: Risks to public health on passenger conveyances are mitigated through the development and implementation of emergency preparedness and response policies, programs and training.

Federal Partner: Canadian Institutes of Health Research
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Health and Health Services Advances	Pandemic Preparedness Research Strategic Initiative	$40.9 M The end date of the PPSRI is March 31, 2011, however, additional partner funds are committed in 2011-12	3.8	ER 21.1  ER 21.2
Total CIHR			3.8

Expected Results:

ER 21.1: Progress on funded projects and outcomes of research are reviewed.

ER 21.2: Uptake of research results is facilitated, and consultations on future research needs are completed through reports and meetings of researchers, stakeholders and decision makers.

Federal Partner: Canadian Food Inspection Agency
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Animal Health and Zoonotics Program / Internal Services	Enhanced enforcement measures	Ongoing	1.5	ER 22.1
	Avian biosecurity on farms	Ongoing	2.7	ER 23.1
	Real property requirements	$4.0M (2006-07 to 2007-08)	0.0	ER 24.1
	Domestic and wildlife surveillance	Ongoing	3.1	ER 25.1
	Strengthened economic and regulatory framework	Ongoing	0.9	ER 26.1
	Performance and evaluation	Ongoing	1.2	ER 27.1
	Risk communications	Ongoing	1.6	ER 28.1
	Field training	Ongoing	1.1	ER 29.1  ER 29.2
	AI enhanced management capability	Ongoing	1.0	ER 30.1
	Updated emergency response plans	Ongoing	2.0	ER 31.1
	Risk assessment and modelling	Ongoing	2.0	ER 32.1
	AI Research	Ongoing	1.5	ER 33.1
	International collaboration	Ongoing	1.6	ER 34.1
	Animal vaccine bank	$0.9M (2006-07 to 2008-09)	0.0	ER 35.1
	Access to antivirals	Ongoing	0.1	ER 36.1
	Specialized equipment	$20.7M (2006-07 to 2008-09)	0.0	ER 37.1
	Laboratory surge capacity and capability	Ongoing	3.7	ER 38.1
	Field surge capacity	Ongoing	1.0	ER 39.1
	National veterinary reserve	Ongoing	0.8	ER 40.1
Total CFIA			25.8

Note: Total CFIA planned spending reflects adjustments made to federal funding allocation due to Strategic Review.

Expected Results:

ER 22.1: Increased capacity to support enhanced screening procedures for live birds or poultry products at Canada’s ports of entry with a view to mitigating the risk of future avian influenza outbreaks in Canada.

ER 23.1: Continuation of stakeholder and general public education, communications and outreach programs in support of the implementation of the National Avian On Farm Biosecurity Standard. Provide stakeholder consultations and develop communication tools to expand education and awareness to the poultry industry service sector.

ER 24.1: No planned expenditures as investments were realized in previous fiscal years.

ER 25.1: Enhanced/integrated Canadian surveillance system, supported by a robust systems platform and the analysis and interpretation of the data collected to allow more timely identification of potential outbreaks, and more timely response to avian influenza situations. Targeted wild bird surveillance plan for 2011 is currently being reviewed. The Canadian Notifiable Avian Influenza Surveillance System is entering its fourth year of operations, providing a real time relay of sampling and reporting of flock status through the National Centre for Foreign Animal Disease.

ER 26.1: Initiatives to strengthen regulatory capacity during outbreaks, including a review and analysis of current legislative/regulatory framework continues.

ER 27.1: Management and evaluation of CFIA’s AI activities, including ongoing performance measurement to monitor results.

ER 28.1: Continued implementation of the “Be Aware and Declare” international border biosecurity outreach campaign. Ongoing media monitoring and training and risk communications related to AI prevention, preparedness and response activities.

ER 29.1: Continued training that will contribute to a skilled and experienced workforce ready to respond to an AI outbreak. A national training initiative for avian influenza response in three core areas is scheduled for the winter of 2011.

ER 29.2: Continued development of training materials (instructor-led and e-learning) in support of emergency response procedures and plans and of trainers in support of end-user training.

ER 30.1: A multi-disease version for the Canadian Emergency Management Response System (CEMRS) application for national surveillance/outbreak use will be available. Translation of CEMRS is currently underway. CEMRS is now used routinely for outbreak document management.

ER 31.1: Continued development and updating of emergency response procedures and plans.

ER 32.1: Continued development of models to better understand the influence and interaction of various factors on the spread of AI and the effectiveness of the various methods used to control and eradicate the disease. A retrospective analysis of the data arising from the 2004 AI outbreak in Abbottsford, BC, is coming to completion after five years' work.  There will be several publications in 2011 describing the key risk factors affecting disease transmission of AI.

ER 33.1: Investment through research in an improved federal capacity for control, risk assessment, diagnostics and vaccines on avian influenza issues will allow a better understanding of the spread of influenza and the effectiveness of disease control measures. These investments will allow more timely and evidence-based decision making on avian influenza responses, thus helping to reducing the risk of transmission to humans and mitigating economic and production losses.

ER 34.1: CFIA staff continue to provide assistance to the World Organisation for Animal Health (OIE) Central Bureau in the Communications Department in an effort to promote the development and implementation of science based standards. Furthermore, the CFIA continues to support the OIE's mandate and efforts to assist member countries in the control and eradication of animal diseases, including zoonotics, through its annual contribution to the OIE. In addition, the CFIA continues to support the development of capacity to address emergence of risk at the animal level through the Canadian chapter of Veterinarians Without Borders.

ER 35.1: Future AI vaccines will be purchased on an “as need” basis.

ER 36.1: Maintenance of access protocols and bank of antivirals to provide appropriate protection to federal employees, ensuring a more timely and effective response to an avian influenza situation and better protection of Canadians.

ER 37.1: No planned expenditures as investments realized in previous fiscal years.

ER 38.1: Maintaining, coordinating and managing the Canadian Animal Health Surveillance Network, an integrated network of federal, provincial and university labs. This network allows for rapid testing, detection and reporting of AI.

ER 39.1: Continued development of a viable response plan, including HR capacity and data management tools.

ER 40.1: Continued training of a reserve of professional veterinarians to enhance surge capacity, expertise and rapid response capability for animal disease control efforts.

Total Allocation for All Federal Partners (from Start to End Date)	Total Planned Spending for All Federal Partners for 2011-12
Ongoing	87.4

Results to be Achieved by Non-Federal Partners (if Applicable): N/A

Contact Information:
Dr. John Spika
130 Colonnade Road
Ottawa ON K1A 0K9
613-948-7929
john.spika@phac-aspc.gc.ca

Name of Horizontal Initiative:  Canadian HIV Vaccine Initiative

Name of Lead Department(s): Public Health Agency of Canada (the Agency)

Lead Department Program Activity: Disease and Injury Prevention and Mitigation

Start Date of the Horizontal Initiative: February 20, 2007

End Date of the Horizontal Initiative: March 31, 2017

Total Federal Funding Allocation (Start to End Date): $111 M

Description of the Horizontal Initiative (Including Funding Agreement):  The Canadian HIV Vaccine Initiative (CHVI) is a collaborative undertaking between the Government of Canada (GoC) and the Bill & Melinda Gates Foundation (BMGF) to contribute to the global effort to develop a safe, effective, affordable and globally accessible HIV vaccine. This collaboration, formalized by a Memorandum of Understanding signed by both parties in August 2006 and renewed in July 2010, builds on the Government of Canada’s commitment to a comprehensive, long-term approach to address HIV/AIDS. Participating federal departments and agencies are the Agency, Health Canada, Industry Canada, the Canadian International Development Agency, and the Canadian Institutes of Health Research.

The CHVI’s overall goals are to: advance the basic science of HIV vaccine discovery and social research in Canada and low-and-middle-income countries (LMICs); support the translation of basic science discoveries into clinical research, with a focus on accelerating clinical trials in humans; address the enabling conditions to facilitate regulatory approval and community preparedness; improve the efficacy and effectiveness of HIV Prevention of Mother-to-Child (PMTCT) services in LMICs by determining innovative strategies and programmatic solutions related to enhancing the accessibility, quality, and uptake; and ensure horizontal collaboration within the CHVI and with domestic and international stakeholders.

Shared Outcome(s):  

Immediate (1-3 years) Outcomes

• Increased and improved collaboration and networking among researchers working in HIV vaccine discovery and social research in Canada and in LMICs;
• Greater capacity for vaccines research in Canada;
• Enhanced knowledge base;
• Increased readiness and capacity in Canada and LMICs; and
• An Alliance Coordinating Office established.

Intermediate Outcomes

• Strengthened contribution to global efforts to accelerate the development of safe effective, affordable, and globally accessible HIV vaccines;
• An increase in the number of women receiving a complete course of anti-retroviral prophylaxis to reduce the risk of mother to child transmission of HIV; and
• A CHVI Research and Development Alliance established.

Long-Term Outcomes

• The CHVI contributes to the global efforts to reduce the spread of HIV/AIDS particularly in LMICs.

Governance Structure(s): The Minister of Health, in consultation with the Minister of Industry and the Minister of International Cooperation, is the lead Minister for the CHVI. An Advisory Board will be established and be responsible for making recommendations to responsible Ministers regarding projects to be funded and will oversee the implementation of the Memorandum of Understanding between the GoC and the BMGF. The CHVI Secretariat, housed in PHAC will continue to provide a coordinating role to the GoC and the BMGF.

Planning Highlights: In 2011-12, CHVI participating departments and agencies will continue to implement activities initiated in 2010-11. For example, the selection process for the Alliance Coordinating Office; the establishment of a HIV vaccine translational support fund to assist researchers in moving HIV vaccine candidates from preclinical research into clinical trials; the completion and awarding of CIDA-CIHR large team grants; the establishment of a new transfer payment fund to encourage private sector participation; and CHVI regulatory capacity-building activities.

In addition, community-based initiatives, research projects approved in 2009-10/2010-11 and support to the Global HIV Vaccine Enterprise will continue in 2011-12. New activities planned for 2011-2012 include the establishment of the Alliance Coordinating Office; provision of training and mentoring programs for capacity building to address identified needs of developing national regulatory authorities; and enhancement of the access, quality and uptake of PMTCT services.

Federal Partner: The Agency
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Disease and Injury Prevention and Mitigation	Infectious Disease Prevention and Control	5.5	1.5	ER 1.1
		5.0	0.5	ER 2.1  ER 2.2
		7.5	0.8	ER 3.1  ER 3.2  ER 3.3
Total PHAC		18.0	2.8

Expected Results:

ER 1.1: New vaccine policy approaches and increased community involvement.

ER 2.1: Efficient and more timely transition from preclinical research into clinical trials.

ER 2.2: Increased number of clinical trial lots manufactured for promising HIV vaccine candidates.

ER 3.1: Establishment of a strong and vibrant network of HIV vaccine researchers and other vaccine researchers both in Canada and internationally.

ER 3.2: Development of innovative solutions to the challenges facing HIV vaccine research and development (such as strengthening career development opportunities for young and early-career investigators).

ER 3.3: Effective communications, strategic planning, coordination, reporting and evaluation within the Government of Canada.

Federal Partner: Health Canada
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Internal Services	Governance and Management Support Services	1.0	0.1	ER 4.1
Health Products	Regulatory Capacity Building Program for HIV Vaccines	4.0	0.8	ER 5.1  ER 5.2
Total HC		5.0	0.9

NOTE: Health Canada/IAD is awaiting TBS approval of supps. B

Expected Results:

ER 4.1: Promote the harmonization and exchange of domestic and international best practices, policies and protocols related to the regulation of vaccines and clinical trials.

ER 5.1: Ensure that trials with HIV vaccines are performed in accordance with the internationally accepted principles of Good Clinical Practices.

ER 5.2: Strengthen the regulatory capacity of developing national regulatory authorities targeted for vaccine and clinical trial submissions, including those related to HIV/AIDS.

Federal Partner: Industry Canada
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Commercialization and Research and Development Capacity in Targeted Canadian Industries	Industrial Research Assistance Program’s Canadian HIV Technology Development Component	13.0	2.5	ER 6.1
Total IC		13.0	2.5

Expected Results:

ER 6.1: Further advancement of new and innovative technologies in pre-commercial development at small and medium- sized enterprises that operate in Canada for the prevention, treatment and diagnosis of HIV.

Federal Partner: Canadian International Development Agency
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Global Engagement and Strategic Policy	International Development Assistance Program	16.0	4.1	ER 7.1
		12.0	0.8	ER 8.1
		30.0	6.0	ER 9.1
		2.0	0.5	ER 10.1
Total CIDA		60.0	11.4

Expected Results:

ER 7.1: Increased capacity to conduct high-quality clinical trials of HIV vaccine and other related prevention technologies in LMICs through new teams of Canadian and LMICs researchers and research institutions.

ER 8.1: In collaboration with CIHR, increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs through the successful completion of the development stage of the Team Grant program to support collaborative teams of Canadian and LMIC researchers.

ER 9.1: Increased number of women receiving a complete course of anti-retroviral prophylaxis to reduce the risk of mother to child transmission of HIV.

ER 10.1: Increased capacity of regulatory authorities in LMICs especially those where clinical trials are planned or ongoing, through training and networking initiatives.

Federal Partner: Canadian Institutes of Health Research
($ M)

Federal Partner Program Activity	Names of Programs for Federal Partners	Total Allocation (from Start to End Date)	Planned Spending for 2011-12	Expected Results for 2011-12
Health and Health Services Advances	Institute Strategic Advances – HIV/AIDS	15.0	1.5	ER 11.1
Total CIHR		15.0	1.5

Expected Results:

ER 11.1: Increased capacity and greater involvement and collaboration amongst researchers working in HIV vaccine discovery and social research in Canada and in LMICs through:

• Ongoing support for operating and catalyst grants undertaken by Canadian researchers;
• Ongoing support for two emerging teams of Canadian researchers; and
• Collaboration with CIDA in award and support of the Large Team Grant program for collaborative teams of Canadian and LMIC researchers.

($ M)

Total Allocation for All Federal Partners (from Start to End Date)	Total Planned Spending for All Federal Partners for 2011-12
111.0	19.0

Results to be Achieved by Non-Federal Partners (if Applicable): Non-governmental stakeholders (including research institutions and not-for-profit community organizations) are integral to the success of the CHVI. Their role is to engage and collaborate with participating departments and agencies, the Bill & Melinda Gates Foundation and other funders to contribute to the CHVI goals and to Canada’s contribution towards the Global HIV Vaccine Enterprise.

Contact Information:
Steven Sternthal
200 Eglantine Driveway
Ottawa, Ontario K1A 0K9
613-952-5120
steven.sternthal@phac-aspc.gc.ca